The microbiome drug developer took its total series C funding to more than $62m, adding $16.6m from investors including Symbiosis, JSR and Bristol-Myers Squibb.

Translation technology provider Unbabel boosted its total funding to $91m in a round that included existing investors M12 and Samsung Next.

Strategic partner RXR Realty joined GV to co-lead a series B round that will fund the expansion of Kitchen United’s network of food delivery hubs.

Merck & Co has contributed to Themis’ series D round after signing a strategic partnership agreement last month to develop vaccines for undisclosed diseases.

Moti has received funding from SIG Asia to close its series A round following a $31m first tranche in July.

Boundless Bio, which is developing treatments focusing on extrachromosomal DNA, has raised $46.4m from investors including Alexandria Venture Investments.

The Lundbeck and Upsher-Smith-backed drug development technology provider reportedly raised the funding at half the $2bn valuation of its last round in 2018.

High school esports platform developer PlayVS, which counts Adidas, Samsung Next and WndrCo as investors, secured series C cash to take its total funding to $96m.

Edgewise Therapeutics completed a $50m round co-led by Novo that will advance product candidates addressing Duchenne and Becker muscular dystrophy.

The diabetes management app developer raised $40m in a round led by Bayer, which has also signed a licensing agreement with the company.